Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Recruiting
Sponsor: Corcept Therapeutics
No Placebo Group
Trial Summary
What is the purpose of this trial?This trial tests how the drug miricorilant behaves in people with normal livers and those with moderate liver issues, including some with NASH. It aims to see if liver problems affect how the drug is processed in the body.
Eligibility Criteria
This trial is for adults with moderate liver problems (hepatic impairment) or nonalcoholic fatty liver disease, who are not heavy smokers and have stable body weight. They must be able to swallow tablets, not have had significant alcohol use recently, and agree to contraception if applicable. People with severe liver issues, recent major illnesses or surgeries, uncontrolled diabetes or other serious health conditions cannot join.Treatment Details
The study tests how a single dose of the drug Miricorilant behaves in the body when someone has moderate liver problems compared to those with normal liver function. It's looking at whether having a fatty liver changes how the drug works after one oral dose.
3Treatment groups
Experimental Treatment
Group I: No Hepatic ImpairmentExperimental Treatment1 Intervention
Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
Group II: Moderate Hepatic ImpairmentExperimental Treatment1 Intervention
Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
Group III: Mild Hepatic ImpairmentExperimental Treatment1 Intervention
Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Site 01Miami, FL
Site 02Miami Lakes, FL
Loading ...
Who is running the clinical trial?
Corcept TherapeuticsLead Sponsor